Ono enters discovery agreement with Xention
This article was originally published in Scrip
Japan's Ono Pharmaceutical has entered an agreement with Xention for the discovery of novel small molecules targeting ion channels. The private UK firm will receive an up-front payment and milestones, as well as research funding for the initial two-year term of the programme.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.